No Data
No Data
Laimei Pharmaceutical (300006.SZ): CUD005 injection approved to conduct clinical trials to treat decompensated liver cirrhosis
Laimei Pharmaceutical (300006.SZ) announced that the company participated in the company Sichuan Kangdesai Medical Technology Co., Ltd. (abbreviation “...
Express News | Laimei Pharmaceutical: The participating company obtained the CUD005 injection clinical trial approval notice
Laimei Pharmaceutical (300006.SZ) subsidiary's endoscopic products obtained medical device registration certificate
Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Hainan Laimei Medical Devices Co., Ltd. (hereinafter referred to as “Laimei Medical Devices”), a holding subsidiary of the company, received two “medical device registration certificates” issued by the Hainan Drug Administration. The products are: “electromechanical endoscopic image processor” and “disposable electronic bronchial imaging catheter”. The single-use electronic bronchial imaging catheter and electronic endoscopic image processor, which obtained the “Medical Device Registration Certificate” this time, is an endoscopic product developed by Laimei Medical Devices. This product can directly observe patient images, which is beneficial
Laimei Pharmaceutical (300006.SZ): net loss of 8.9273 million yuan in 2023
Gelonghui, March 22丨Laimei Pharmaceutical (300006.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 896 million yuan, an increase of 1.24% over the previous year; net profit attributable to shareholders of listed companies was -8.9273 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -59.333 million yuan; and basic earnings per share was -0.0085 yuan.
Express News | The ban on restricted stocks with a market capitalization of 11.182 billion yuan was lifted today. Among them, drones ranked first with a market capitalization of 3.137 billion yuan
Laimei Pharmaceutical (300006.SZ): The ban on 244 million restricted shares will be lifted on March 22
On March 19, Ge Longhui Pharmaceutical (300006.SZ) announced an indicative announcement on the listing and circulation of restricted shares issued to specific targets. The shares that have been lifted are the company's shares issued to specific targets in 2021. The total number of shareholders applying to lift sales restrictions is 3. The number of shares that have been lifted this time is 244 million shares, accounting for 23.08% of the company's total share capital. The listing and circulation date for the shares whose sales restrictions have been lifted is March 22, 2024 (Friday).
No Data